Ascendis Pharma A/S (ASND) Q4 2022 Results Conference Call February 16, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director of Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President, Chief Financial Officer Stina Singel - Executive Vice President, Head of Clinical Development Oncology Joe Kelly - Senior Vice President, Head of U.S. Commercial Endocrinology Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Da ...

财务表现 - Ascendis Pharma 全年2022年度总收入为 5120 万欧元，较2021年的 778 万欧元增长显著[6] - 研发费用在2022年达到 3.796 亿欧元，较2021年的 2.959 亿欧元有所增加[7] - 销售、一般和管理费用在2022年为 2.212 亿欧元，较2021年的 1.602 亿欧元有所增加[8] - Ascendis Pharma 2022年度净亏损为 5.832 亿欧元，较2021年的 3.836 亿欧元有所增加[10] 资产状况 - Ascendis Pharma 截至2022年12月31日的现金、现金等价物和可市场化证券总额为 7.429 亿欧元，较2021年底的 7.896 亿欧元略有下降[11] - Ascendis Pharma A/S 2022年12月31日的总资产为1,089,738,000欧元，较2021年同期略有增长[20] - 公司2022年12月31日的现金及现金等价物为444,767,000欧元，较2021年同期持平[20] - Ascendis Pharma A/S 2022年12月31日的非流动资产中，投资占比较高，为166,267,000欧元[20] 负债情况 - 公司2022年12月31日的负债总额为826,390,000欧元，较2021年同期大幅增长[20] 股本情况 - Ascendis Pharma A/S 2022年12月31日的股本为7,675,000欧元，较上年略有增长[20]

中国市场表现 - 公司财报电话会议中提到，公司在中国市场创下了iPhone销售收入纪录[110] 产品发展 - 公司表示将继续发展新产品和技术，包括在肿瘤学和眼科领域的产品候选品[7] - 公司强调了对产品和产品候选品的商业化、市场推广和制造能力的期望[7] 全球战略 - 公司计划在全球范围内实施商业模式和战略计划，包括全球商业化策略[8]

Ascendis Pharma A/S (ASND) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President & Chief Executive Officer Scott Smith - Senior Vice President & Chief Financial Officer Stina Singel - Head of Clinical Development Oncology Birgitte Volck - Senior Vice President Head of Clinical Development & Medical Affairs Endocrinology Rare Diseases Joe Kelly - Head of US Commercial Endocrinology Conference Call Participants ...

Ascendis Pharma A/S (ASND) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Senior Vice President and Chief Financial Officer Dana Pizzuti - Head, Development Operations and Chief Medical Officer Stina Singel - Head, Clinical Development Oncology Joe Kelly - Head, U.S. Commercial Endocrinology Conference Call Participants Jessica Fye - JPMorgan Josh Schimmer - Eve ...

Ascendis Pharma A/S (ASND) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jan Mikkelsen – President and Chief Executive Officer Scott T. Smith – Senior Vice President and Chief Financial Officer Timothy J. Lee – Senior Director of Investment Officer Dr. Dana Pizzuti – Head of Development Operations and Chief Medical Officer Dr. Stina Singel – Senior Vice President, Head of Clinical Development, Oncology Conference Call Participants Jessica Fye – JPMorgan Josh Schimmer – Everco ...